Known targets — ChEMBL curated mechanism
ACHECHRM1CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNG
The experimentally established mechanism targets of Iodide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | BRD4 | O60885 | 3/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.33 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12220240 | 0.97 | GAA (0.60) | GAAALDH1A1KMT2AKDM4EMAPT | |
| Acetic Acid SCHEMBL27980670 | 0.87 | GAA (0.50) | GAAALDH1A1KDM4EMAPTHPGD | |
| SCHEMBL28276832 | 0.83 | GAA (0.47) | GAAKMT2ATSHRSMN1; SMN2POLB | |
| SCHEMBL27980063 | 0.82 | GAA (0.46) | GAAKMT2ATSHRSMN1; SMN2POLB | |
| SCHEMBL27980234 | 0.79 | GAA (0.42) | GAAALDH1A1KMT2AMAPTRAB9A | |
| SCHEMBL27980259 | 0.79 | GAA (0.43) | GAAALDH1A1KMT2AKDM4EMAPT | |
| Bromide SCHEMBL2195679 | 0.75 | ALDH1A1 (0.41) | GAAALDH1A1KMT2ANPC1POLB | |
| SCHEMBL7088419 | 0.73 | ALDH1A1 (0.47) | ALDH1A1KMT2ABRD4MAOANPC1 | |
| Iodide SCHEMBL30935723 | 0.70 | ALDH1A1 (0.58) | GAAALDH1A1KMT2AKDM4EMAPT | |
| Iodide SCHEMBL354263 | 0.70 | ALDH1A1 (0.58) | GAAALDH1A1KMT2AKDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8980875-B2 | Platinum-N-heterocyclic carbene derivatives, preparation thereof and therapeutic use thereof | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2015-03-17 | — | — | US | disclosed |
| US-8632914-B2 | Triazolium and imidazolium salts and uses thereof | UNIVERSITY HEALTH NETWORK (CA) | 2014-01-21 | — | — | US | disclosed |
| US-20130338128-A1 | PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2013-12-19 | — | — | US | disclosed |
| US-8481522-B2 | Platinum-N-heterocyclic carbene derivatives, preparation thereof and therapeutic use thereof | SANOFI (FR) | 2013-07-09 | — | — | US | disclosed |
| US-20110257235-A1 | TRIAZOLIUM AND IMIDAZOLIUM SALTS AND USES THEREOF | UNIVERSITY HEALTH NETWORK (CA) | 2011-10-20 | — | — | US | disclosed |
| US-20110172199-A1 | PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2011-07-14 | — | — | US | disclosed |
| WO-2010025558-A1 | TRIAZOLIUM AND IMIDAZOLIUM SALTS AND USES THEREOF AS ANTIMALARIALS | UNIVERSITY HAEALTH NETWORK (CA) | 2010-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257235-A1 | TRIAZOLIUM AND IMIDAZOLIUM SALTS AND USES THEREOF | ARG2, ARG1, CIT | GAA 3392/4885ALDH1A1 3979/4885KMT2A 3456/4885 |
| US-20130338128-A1 | PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SCO2, C3AR1, IDH1 | GAA 4532/4885ALDH1A1 1989/4885KMT2A 4286/4885 |
| US-20110172199-A1 | PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SCO2, C3AR1, IDH1 | GAA 4532/4885ALDH1A1 1989/4885KMT2A 4286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.